Mast cells respond to a wide range of signals — IgE, complement, neuropeptides, CRH, estrogen, TLR ligands, certain foods, certain metals, certain drugs, and physical triggers — and "total load" (multiple small triggers stacking) is a clinically useful heuristic. But each individual trigger needs its own evidence audit, and most claims about a "trigger" are at best mechanistically plausible and at worst marketing-grade speculation.

This file scores the specific trigger/comorbidity hypotheses @BioavailableNd promotes. Ratings use the Source Evaluation Framework (5 = RCT/SR; 1 = anecdote); translation levels T0–T5; causal confidence low/moderate/high per Bradford-Hill add-on.

01Triggers Andra names

Stress, CRH, and the mast cell–gut axis

Andra's claim: chronic stress is a primary driver; mast cells respond to CRH.
What the literature says: psychological stress and exogenous CRH increase intestinal permeability in humans in a mast-cell-dependent mechanism (PMID 24153250, n=11 healthy controls, CRH 1 µg/kg IV; increased permeability blocked by mast-cell stabilizer).[110] CRH receptors on mast cells are well-documented.
Evidence rating: 4. Translation: T4. Causal confidence: moderate. Verdict: Supported mechanism.

Hormones — estrogen

Andra's claim: estrogen activates mast cells; endometriosis, PCOS, and perimenstrual flares reflect this.
What the literature says: E2 directly triggers mast cell degranulation in RBL2H3 cells and in ovarian endometriomas (PMID 29074615); mast cell numbers and activation state are elevated in endometriosis lesions and correlate with dysmenorrhea severity.[20][19] Endometriotic cells recruit mast cells via SCF/TGF-β/MCP-1 release in response to E2.[20] A 2016 paper notes that genitourinary mast cells express estrogen, gonadotropin, and CRH receptors and respond to estrogen.[68]
Evidence rating: 4 (mechanism) / 3 (clinical association). Translation: T3–T4. Causal confidence: moderate for reproductive-tissue mast cell activation; weaker for general "E2 → MCAS."
Verdict: Supported for endometriosis/ovarian end-organ; partially supported for systemic E2 → MCAS.

Mold and CIRS

Andra's claim: mold exposure drives mast cell activation; CIRS is essentially an MCAS variant.
What the literature says: the CIRS literature (Shoemaker et al.) shows inflammatory markers (TGF-β1, MMP9, C4a, VEGF) elevated in patients exposed to water-damaged buildings.[28][24][25] Mycotoxin exposure causes immune dysregulation (PMID 29752039, PMID 29880330). Mycotoxins from Fusarium oxysporum cause skin inflammation and mast-cell activation (PMID 19570074).[113]
However: the Aspergillus metabolite gliotoxin directly suppresses mast cell degranulation via calcium and superoxide pathways (PMID 16213796) — the opposite of "mold drives mast cells."[27] The clinical CIRS literature is dominated by a single research group with limited independent replication.[24] A 2024 systematic review of CIRS treatment found only Shoemaker-protocol studies.[24]
Evidence rating: 2. Translation: T2. Causal confidence: low.
Verdict: Plausible symptom overlap; mechanism mixed; evidence is not robust enough to claim mold→MCAS causally.

Nickel and metals

Andra's claim: nickel acts as an estrogen and activates mast cells; nickel drives SNAS, endometriosis, PCOS, eczema, GERD.
What the literature says:
Nickel is a metalloestrogen — it activates estrogen receptor α in vitro and in vivo (PMID 16489580, Martin et al.).[47]
Nickel allergy is associated with endometriosis in two population-based studies — an 11-year nested case-control (PMID 26439741) and a 3-year cross-sectional study showing significantly higher nickel allergy prevalence in endometriosis patients (PMID 25976177).[49][50]
Systemic Nickel Allergy Syndrome (SNAS) is a real entity: cutaneous + GI + extra-cutaneous symptoms in nickel-sensitized individuals after dietary exposure; treated by low-nickel diet, oral hyposensitization, and probiotics.[10][11][81][80][79]
Oral hyposensitization to nickel reduces symptoms and shifts TH1/TH2 cytokine balance (PMID 20378005).[81]
Probiotic supplementation in SNAS reduces lactobacilli population shift and improves symptoms (PMID 25363062).[80]
The role of nickel as a direct mast cell activator (as opposed to a Type IV contact allergen) is less well-documented in non-sensitized individuals; in SNAS patients the clinical picture is mast-cell-like.
Evidence rating: 3 (estrogen-like); 3 (SNAS); 2 (mast cell activator). Translation: T3. Causal confidence: moderate for endometriosis association and SNAS; lower for nickel as a primary MCAS driver.
Verdict: The metalloestrogen and endometriosis links are real; the claim that nickel "activates mast cells" in the way Andra implies is supported only in sensitized individuals.

Infections (post-COVID, Lyme, etc.)

Andra's claim: unresolved infections drive MCAS; long COVID is largely MCAS.
What the literature says:
Mast-cell-related symptoms are highly prevalent in long COVID (PMID 34563706, Afrin et al.).[38]
Viral infections and vaccinations can trigger chronic urticaria (PMID 37515272).[122]
Famotidine (H2 blocker) reduced cytokine storm and improved POTS-like hyperadrenergic POTS in a single case report (PMID 38526146).[67]
COVID vaccines can transiently worsen mast cell symptoms in susceptible patients (PMID 38176772, 34791757).[64][125]
However, the same 2024 single-center study (PMID 38056692) that tested suspected MCAS patients found that very few met consensus-1 criteria, suggesting post-COVID symptoms that feel like MCAS often have other explanations (autonomic dysfunction, EBV reactivation, hypermobility spectrum disorder).[128]
Evidence rating: 3. Translation: T3. Causal confidence: moderate for symptom overlap; lower for full MCAS criteria.
Verdict: Real symptom overlap with MCAS; under strict criteria, fewer than expected meet full MCAS diagnosis.

Foods (other than dairy)

Andra's claim: high-histamine foods, fermented foods, wine trigger MCAS.
What the literature says: a 2025 review of histamine content in Brazilian foods shows the expected high-histamine categories (aged cheeses, fermented vegetables, cured meats, wine, certain fish).[70] Wine-induced headache involves histamine among other amines (PMID 36514756, 27699780, 15806385).[136][137][138] Low-histamine diets show modest efficacy in atopic dermatitis (PMID 40431369) and chronic urticaria (PMID 34826140, 39236849, 40880715).[39][120][119][118]
Evidence rating: 3. Translation: T3. Causal confidence: moderate for HIT subgroup; low for MCAS subgroup.
Verdict: Supported for HIT; not specifically demonstrated for MCAS.

02Comorbidities Andra lists

Condition	Evidence link to MCAS	Citation
Endometriosis	Moderate; mast cells in lesions, E2-driven activation, nickel-allergy association	[19][20][49][50]
PCOS	None direct; some via obesity/insulin resistance/DAO deficiency; one Andra-specific claim	[unverified]
Eczema / atopic dermatitis	Moderate; low-histamine diet helps subgroup, [EAS] dietary amine elimination shows effect	[39][143]
GERD	Weak; histamine can trigger gastric acid; some overlap	[73]
Rosacea	Strong for mast cell involvement; H. pylori link disproven in MR studies	[60][61][140][142]
IBS / SIBO	Moderate; mast cell density increased in IBS mucosa; stress-mast cell-permeability axis	[109][110][139]
Hyperadrenergic POTS / Dysautonomia	Strong clustering; "firmly established" 2024	[147][71][126]
Hypermobile EDS	Strong clustering; GI manifestations reviewed by AGA	[147][71][145]
Long COVID	Moderate symptom overlap; small minority meet consensus-1 MCAS	[38][21][128]
Fibromyalgia	Positive small RCT for DAO supplementation; modest mechanistic support	[82]
Chronic urticaria	Direct relationship; treated with omalizumab	[69][122]
ADHD	Mechanistic animal only (H2 → dopamine); no human MCAS trial	[55][56][57]

Swipe table →

03Speculative links (low evidence)

Claim	Evidence rating	Translation	Verdict
ADHD as "a histamine problem"	1	T1	Mechanistic animal data (H2 receptor on parvalbumin neurons in substantia nigra; H2 modulation of striatal dopamine); no human MCAS-ADHD trial. Hypothesis, not treatment.
nnEMF drives MCAS	1	T1	Animal histology only (atrazine + 50 Hz EMF combined exposure increased cutaneous mast cell degranulation in juvenile rats; ELF-EMF increased thyroid mast cell density); no human MCAS trial.
Limbic "danger mode" / DNRS as MCAS treatment	1	T0–T1	No primary MCAS trial of Annie Hopper's DNRS or any limbic-retraining program in MCAS specifically. Theoretical.
Organotherapy for MCAS	1	T0	Historical practice; no modern trial.
Cell salts / biochemic tissue salts for MCAS	1	T0	No peer-reviewed trial in MCAS or any related condition.
MCAS causes weight gain or lipedema	1	T0	Andra has written about this on Substack; no primary literature supports a direct lipedema-MCAS causal mechanism.

Swipe table →

04Method note

Each claim is rated against the strongest available primary literature. The "androgenic" / "estrogenic" / "allergic" / "neurological" / "autoimmune" / "metabolic" lines are kept separate because the evidence base differs across them.

05Notes

The single most useful clinical test of "does this patient's MCAS respond to addressing the trigger?" is the provocation-and-dechallenge design: e.g., nickel avoidance + low-nickel diet in suspected SNAS + MCAS, then re-introduction.
For the "total load" model, the practical question is which triggers actually matter for this patient — the patient can only work the list that applies to them, not the full population-level list.
The fact that mast cells express receptors for estrogen, CRH, neuropeptide Y, substance P, IgE, complement, and TLR ligands is why they sit at the center of so many chronic-disease hypotheses. It is also why so many of those hypotheses are unfalsifiable without objective mediator measurement.

06Connections

Neighborhood · 6 linked entriesOpen full map →

07Sources

PubMed 24153250PubMed 24153250
PubMed 29074615PubMed 29074615
PubMed 29752039PubMed 29752039
PubMed 29880330PubMed 29880330
PubMed 19570074PubMed 19570074
PubMed 16213796PubMed 16213796
PubMed 16489580PubMed 16489580
PubMed 26439741PubMed 26439741
PubMed 25976177PubMed 25976177
PubMed 20378005PubMed 20378005
PubMed 25363062PubMed 25363062
PubMed 34563706PubMed 34563706
PubMed 37515272PubMed 37515272
PubMed 38526146PubMed 38526146
PubMed 38176772PubMed 38176772
PubMed 38056692PubMed 38056692
PubMed 36514756PubMed 36514756
PubMed 40431369PubMed 40431369
PubMed 34826140PubMed 34826140
PubMed 41994619PubMed 41994619
PubMed 21409856PubMed 21409856
PubMed 31424502PubMed 31424502
PubMed 35785029PubMed 35785029
PubMed 39649915PubMed 39649915
PubMed 25889530PubMed 25889530
PubMed 36069791PubMed 36069791
PubMed 42763339PubMed 42763339
PubMed 40355265PubMed 40355265
PubMed 39788124PubMed 39788124
PubMed 2221490PubMed 2221490
PubMed 2731601PubMed 2731601
PubMed 35736349PubMed 35736349
PubMed 42807181PubMed 42807181
PubMed 41256231PubMed 41256231
PubMed 40387691PubMed 40387691
PubMed 42039449PubMed 42039449
PubMed 36143107PubMed 36143107
PubMed 37892588PubMed 37892588
PubMed 32649443PubMed 32649443
PubMed 40880715PubMed 40880715
PubMed 39236849PubMed 39236849
PubMed 34791757PubMed 34791757
PubMed 40809669PubMed 40809669
PubMed 27699780PubMed 27699780
PubMed 15806385PubMed 15806385
PubMed 42346839PubMed 42346839
PubMed 42515667PubMed 42515667
PubMed 40963887PubMed 40963887
PubMed 34564936PubMed 34564936
PubMed 42788166PubMed 42788166
PubMed 40352770PubMed 40352770

08Entry history

16 Oct 2026